VOLTAS brings ETO sterilization in-house to cut validation time in half

VOLTAS says its ISO 13485-compliant facility in Cottage Grove, Minnesota now offers in-house ethylene oxide sterilization for medical devices, reducing validation time by 50% versus outsourced workflows at the same cost. The move is meant to keep assembly, packaging, validation, and documentation under one roof for single-use devices and commercial production.

Why it matters: - Medical device makers can keep sterilization inside the same facility as assembly and packaging, reducing handoffs and vendor coordination. - VOLTAS says the in-house model cuts sterilization validation time by 50% compared with traditional outsourced processes, without adding cost for customers. - The setup is aimed at single-use devices that cannot withstand heat or radiation sterilization.

What happened: - VOLTAS launched in-house ethylene oxide, or ETO, sterilization services at its ISO 13485-compliant facility in Cottage Grove, Minnesota. - The service is available now to startups and established device manufacturers working with VOLTAS. - The company says it can run sterilization for development-stage builds and ongoing commercial volumes.

The details: - VOLTAS supports ETO runs from small routine batches to full pallet sterilization. - The company pairs sterilization with sterile barrier packaging and labeling, full sterilization validation, cycle development, cleanroom assembly, and regulatory documentation support. - ETO sterilization lets a device move from cleanroom assembly through a validated cycle without leaving the building. - VOLTAS says that approach preserves full traceability throughout the process. - The company says manufacturers no longer need to wait for an external lab schedule or manage a separate vendor relationship for validation and documentation.

Between the lines: - Bringing sterilization in-house can reduce process risk by limiting the number of transfers between vendors. - A single project team handling assembly, packaging, sterilization, and regulatory work can also simplify communication during submissions and audits. - VOLTAS is positioning sterilization as part of a broader integrated manufacturing and development model, not as a stand-alone service.

What's next: - VOLTAS says it will continue offering ETO sterilization for terminal sterilization studies, hardest-to-sterilize studies, and commercial production. - The company is also expected to use the in-house model to support faster development timelines for customers moving from concept to commercialization. - Medical device teams interested in the service can contact VOLTAS or book a meeting through the company website.

The bottom line: - VOLTAS is betting that faster validation, fewer handoffs, and a single documentation trail will make in-house ETO sterilization more attractive than outsourcing for device makers.